Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors
- PMID: 10509562
- DOI: 10.1097/00002030-199909100-00004
Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors
Abstract
Objectives: To determine the effect of the protease inhibitors ritonavir, nelfinavir and indinavir on the P-glycoprotein (P-gp)-mediated transport of saquinavir in Caco-2 cell monolayers. To study the modulation of P-gp function in human lymphocytes by saquinavir, ritonavir, nelfinavir and indinavir.
Methods: We examined the effect of the protease inhibitors on P-gp function in human lymphocytes by using Rhodamine 123 (Rh 123; a fluorescent substrate of P-gp) by flow cytometry. Efflux of Rh 123 correlates with P-gp function and inhibition of P-gp results in dye retention. Verapamil, a P-gp modulator and inhibitor of active transport at 4 degrees C was used as a positive control. The transport of [14C]saquinavir (1 microM) across Caco-2 cell monolayers was investigated, alone and in the presence of verapamil and ketoconazole (500 microM) and the protease inhibitors at 100 microM. Caco-2 cells are an in vitro model of the intestinal epithelium that is widely used for the study of P-gp function. The transport of saquinavir was determined in both the apical to basolateral (AP-BL) and basolateral to apical (BL-AP) directions.
Results: Saquinavir and ritonavir (10 microM) markedly inhibited Rh 123 efflux with an increase in fluorescence intensity similar to that obtained with verapamil. A small but statistically significant increase in fluorescence intensity was observed with nelfinavir; however indinavir did not modulate Rh 123 efflux. In Caco-2 cells the apparent permeability coefficient for BL-AP efflux of saquinavir exceeded that for AP-BL efflux by a factor of 26: this is indicative of an active efflux pump. Known P-gp modulators caused a decrease in BL-AP efflux and an increase in AP-BL transport. The protease inhibitors displayed some P-gp modulation with ritonavir having the most potent effect.
Conclusions: We have demonstrated that saquinavir is a substrate for P-gp and that ritonavir, nelfinavir and indinavir modulate P-gp function in both human lymphocytes and Caco-2 cells.
Similar articles
-
Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-1 protease inhibitor saquinavir by grapefruit juice components.Br J Clin Pharmacol. 1999 Oct;48(4):543-52. doi: 10.1046/j.1365-2125.1999.00052.x. Br J Clin Pharmacol. 1999. PMID: 10583025 Free PMC article.
-
HIV-protease inhibitors contribute to P-glycoprotein efflux function defect in peripheral blood lymphocytes from HIV-positive patients receiving HAART.J Acquir Immune Defic Syndr. 2001 Aug 1;27(4):321-30. doi: 10.1097/00126334-200108010-00001. J Acquir Immune Defic Syndr. 2001. PMID: 11468419
-
Active apical secretory efflux of the HIV protease inhibitors saquinavir and ritonavir in Caco-2 cell monolayers.Pharm Res. 1998 Mar;15(3):423-8. doi: 10.1023/a:1011924314899. Pharm Res. 1998. PMID: 9563072
-
The choice of HIV protease inhibitor: indinavir is currently the best option.Prescrire Int. 1999 Apr;8(40):55-60. Prescrire Int. 1999. PMID: 10848067 Review.
-
Clinical pharmacology of HIV protease inhibitors: focus on saquinavir, indinavir, and ritonavir.Pharm World Sci. 1997 Aug;19(4):159-75. doi: 10.1023/a:1008629608556. Pharm World Sci. 1997. PMID: 9297727 Review.
Cited by
-
Exploring bat-inspired cyclic tryptophan diketopiperazines as ABCB1 Inhibitors.Commun Chem. 2024 Jul 13;7(1):158. doi: 10.1038/s42004-024-01225-z. Commun Chem. 2024. PMID: 39003409 Free PMC article.
-
Clinical Implications of P-Glycoprotein Modulation in Drug-Drug Interactions.Drugs. 2017 May;77(8):859-883. doi: 10.1007/s40265-017-0729-x. Drugs. 2017. PMID: 28382570 Review.
-
Differential modulation of P-glycoprotein expression and activity by non-nucleoside HIV-1 reverse transcriptase inhibitors in cell culture.Pharm Res. 2002 Jul;19(7):1038-45. doi: 10.1023/a:1016430825740. Pharm Res. 2002. PMID: 12180537
-
Pharmacokinetic interactions between ritonavir and quinine in healthy volunteers following concurrent administration.Br J Clin Pharmacol. 2010 Mar;69(3):262-70. doi: 10.1111/j.1365-2125.2009.03566.x. Br J Clin Pharmacol. 2010. PMID: 20233197 Free PMC article. Clinical Trial.
-
Rapid assessment of P-glycoprotein inhibition and induction in vitro.Pharm Res. 2003 Aug;20(8):1177-83. doi: 10.1023/a:1025092829696. Pharm Res. 2003. PMID: 12948015
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous